유럽 ​​중부 조숙성 사춘기(CPP) 치료 시장 – 2030년까지의 산업 동향 및 예측

유럽 ​​중부 조숙성 사춘기(CPP) 치료 시장 분석 및 규모

최근 들어, 중추성 조숙성 사춘기(CPP) 치료 시장은 2023-2030년 예측 기간 동안 빠르게 성장할 것으로 예상됩니다. 생식선 자극 호르몬(GnRH) 작용제는 내인성 GnRH의 자극 효과를 제한하고 뼈 발달을 증가시켜 조기 사춘기를 피하기 때문에 CPP를 치료하는 데 널리 사용될 수 있습니다. Triptodor, Lupron Depot-Ped(류프롤리드 아세테이트), Supprelin LA(히스트렐린 아세테이트)가 현재 시중에 판매되는 중추성 조숙성 사춘기에 승인된 세 가지 치료제인 것으로 확인되었습니다.

Data Bridge Market Research는 2023-2030년 예측 기간 동안 중추성 조숙성 사춘기(CPP) 치료 시장의 성장률을 분석합니다. 언급된 예측 기간 동안 중추성 조숙성 사춘기(CPP) 치료 시장의 예상 CAGR은 약 6.7%인 경향이 있습니다. 이 시장은 2022년에 5억 1,050만 달러로 평가되었으며 2030년까지 8억 5,765만 달러로 성장할 것입니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

유럽 ​​중부 조숙성 사춘기(CPP) 치료 시장 범위 및 세분화

Market Definition

Central precocious puberty (CPP) treatment consists of features such as wide presence of novel pipeline drugs that will impact in launching several new products by the manufacturers into the central precocious puberty (CPP) treatment market that will increase its demand as well as high demand of disease specific treatment which leads the demand of accurate central precocious puberty (CPP) treatment. The mutations in the MKRN3 gene are the most commonly known genetic cause of central precocious puberty (CPP).   

Europe Central Precocious Puberty (CPP) Treatment Market Dynamics

Drivers

• Increasing Product Launches and Collaborations

Several product launches and agreements are also started by the major companies’ globally, increasing the central precocious puberty (CPP) treatment market. For instance, AbbVie Inc. collaborated with Scripps Research in december 2019, a company focused on developing new therapeutic approaches to deal with the usual rare diseases. This collaboration aided the company to treat numerous kinds of diseases by improving its drug development procedure which will lead to earn more economic benefit. Furthermore, collaboration, business expansion, product launches, awards and several recognition, also joint ventures and other strategies by the market players is increasing the market growth in the central precocious puberty (CPP) treatment market which also aids in the benefit for organization to further improve their offering for central precocious puberty treatment.

Opportunities

• Increasing Prevalence of CPP in Girls

It has been witnessed that girls segment is dominating in the central precocious puberty (CPP) treatment market as the prevalence of CPP is less common in boys compared to girls and it has the wide presence of high female ratio than the male population. One in every 5,000 to 10,000 girls is seen to be suffering from central precocious puberty. Though the occurrence of the illness is not so clear in boys, it is less widespread in boys. Thus, this boosts the market growth.   

• Rising Adoption of Direct Tender Segment

The direct tender channel is hugely increasing the market growth as the drugs are used for the central precocious puberty (CPP) treatment which can be procured through direct tender on reasonable price and the patients receive treatment for extended period of time. Thus, this factor enhances the market growth.

Restraints/Challenges

• High Cost of Treatment

There are several treatment methods that requires surgery and high-end medications that demand very heavy cost. The lower economic groups cannot access these treatment processes. Thus, this factor hampers the market growth as the treatment options are not feasible for all the economic groups.

• Lack of Reimbursement Policies

There is a lack of reimbursement for central precocious puberty (CPP) treatment, which are projected to limit the market growth. Both public and private payers do not recompense majority of the treatment services. The cost of such services varies hugely and there cannot be any standardization. Thus, this factor hampers the market growth.

This central precocious puberty (CPP) treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the central precocious puberty (CPP) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2019, Ipsen Pharma extended its partnership with Debiopharm associated with Decapeptyl (triptorelin) that is used for CPP treatment to next 15 years. This partnership aided the company to attain a huge growth in its overall revenue by maintaining a continued access of its products to patients.

Europe Central Precocious Puberty (CPP) Treatment Market Scope

The central precocious puberty (CPP) treatment market is segmented on the basis of type, month, route of administration, gender, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Medication
• Surgery

Month

• 1-Month
• 3-Month
• 6-Month
• Others

Route of Administration

• Parenteral
• Oral
• Implants
• Others

Gender

• Girls
• Boys

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Central Precocious Puberty (CPP) Treatment Market Regional Analysis/Insights

The central precocious puberty (CPP) treatment market is analyzed and market size insights and trends are provided by type, month, route of administration, gender, end user and distribution channel as referenced above.

The major countries covered in the central precocious puberty (CPP) treatment market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.

유럽 ​​지역은 2023년부터 2030년까지의 예측 기간 동안 의료비 지출이 증가함에 따라 가장 높은 성장률을 기록할 것으로 예상됩니다.

독일은 효과적인 치료 옵션에 대한 수요가 증가함에 따라 유럽 시장을 선도하고 있습니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 또한 북미 브랜드의 존재와 가용성, 그리고 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다. 

경쟁 환경 및 유럽 중부 조숙성 사춘기(CPP) 치료 시장 점유율 분석

중앙 조숙성 사춘기(CPP) 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 북미 지역 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 제공된 위의 데이터 포인트는 중앙 조숙성 사춘기(CPP) 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

중추성 조숙성 사춘기(CPP) 치료 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 사노피(프랑스)
• 파이저 주식회사(미국)
• GSK plc (영국)
• 노바티스 AG(스위스)
• AbbVie Inc.(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• 마일런 NV(미국)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• Ipsen Pharma(프랑스)
• Arbor Pharmaceuticals (미국)
• Tolmar Pharmaceuticals, Inc. (미국)
• GP Pharm(스페인)
• 데비오팜(스위스)
• 대웅제약(한국)
• Sun Pharmaceutical Industries Ltd. (인도)
• 다케다제약 주식회사(일본)
• 엔도 인터내셔널 주식회사(아일랜드)
• 아스트라제네카(영국)

SKU-55862